Needham Maintains Buy on Phreesia, Raises Price Target to $81

Needham analyst Ryan MacDonald maintains Phreesia (NYSE:PHR) with a Buy and raises the price target from $70 to $81.

byBenzinga Newsdesk

September 2, 2021

1 minute read

Needham analyst Ryan MacDonald maintains Phreesia (NYSE:PHR) with a Buy and raises the price target from $70 to $81.

Avis Budget, Zebra Technologies And Some Other Big Stocks Moving Lower On Tuesday

By Lisa Levin

Today, 11:36 AM

FAT Brands Inc. (NASDAQ: FATBB) fell 30% to $10.50. The company recently posted a Q2 net loss of $8.2 million or $0.50 per share.

ABR

Brandywine Realty Trust Q3 EPS $0.01 Misses $0.02 Estimate, FFO $0.35; Narrows FY21 FFO Guidance From $1.34-$1.40 To $1.35-$1.39

By Benzinga Newsdesk

Today, 11:36 AM

Brandywine Realty Trust (NYSE:BDN) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.02 by 50 percent.

BDN

ESSA Pharma Shares Tank As Janssen Stops Enrollment In EPI-7386 Combo Prostate Cancer Trials

By Vandana Singh

Today, 11:36 AM

ESSA Pharma Inc (NASDAQ:EPIX) announced that Johnson & Johnson’s (NYSE:JNJ) Janssen is suspending enrollment into the Phase 1 study of EPI-7386 with apalutamide or EPI-7386…

EPIX

Analyst Ratings

Where Coty Stands With Analysts

By Benzinga Insights

Today, 11:36 AM

Over the past 3 months, 5 analysts have published their opinion on Coty (NYSE:COTY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

COTY

Needham Maintains Buy on Phreesia, Raises Price Target to $81

Related Posts

Avis Budget, Zebra Technologies And Some Other Big Stocks Moving Lower On Tuesday

Brandywine Realty Trust Q3 EPS $0.01 Misses $0.02 Estimate, FFO $0.35; Narrows FY21 FFO Guidance From $1.34-$1.40 To $1.35-$1.39

ESSA Pharma Shares Tank As Janssen Stops Enrollment In EPI-7386 Combo Prostate Cancer Trials

Where Coty Stands With Analysts